[Geneva, Switzerland – October 22, 2016]
Potentially refutes assumption that Loa Loa is a benign disease and highlights R&D gap for filarial diseases
A filarial worm infection called Loiasis that affects over 10 million people in Africa and has been assumed to be a relatively harmless disease could possibly contribute to increased risk of death, according to a study recently published in Lancet Infectious Diseases.
[Geneva, Switzerland – October 22, 2016]
[Geneva, Switzerland – September 22, 2016]
The Drugs for Neglected Diseases initiative (DNDi) is pleased to announce financial support from the Swiss Government to the DNDi-WHO joint initiative Global Antibiotic Research and Development Partnership (GARDP) launched earlier this year.
As the International AIDS Conference kicks off in Durban, the Drugs for Neglected Diseases initiative (DNDi) has released an update on its efforts to develop optimal child-adapted antiretroviral formulations. This document details some recent progress towards its final goal of developing “4-in-1” fixed-dose combinations using the World Health Organization (WHO) recommended treatment regimen for infants and young children. DNDi’s update also discusses some promising developments for treatment for children living with both HIV and tuberculosis (TB).
[Summit, New Jersey and Geneva, Switzerland – June 15, 2016]
First US-based biopharmaceutical partner to join global consortium
The biopharmaceutical company Celgene has become the fifth company to join the “Neglected Tropical Diseases Drug Discovery Booster” consortium, a new initiative to accelerate and cut the cost of early stage drug discovery for two of the world’s most neglected diseases, leishmaniasis and Chagas disease.
[8 June 2016 – Rio de Janeiro, Brazil]
Plans will boost access to Chagas treatment throughout Americas
In a bid to overturn a situation where less than 1% of people with Chagas disease have access to treatment, non-profit drug development organisation Drugs for Neglected Diseases initiative (DNDi), pharmaceutical company Chemo Group and non-profit foundation Mundo Sano are entering into a formal collaboration to boost affordable access to benznidazole, by registering this essential medicine in countries affected by this deadly disease, including the US.
[1 June 2016 – Tokyo, Japan]
Non-profit research and development organization Drugs for Neglected Diseases initiative (DNDi) welcomes the G7-related announcement from the Government of Japan to replenish the Global Health Innovative Technology Fund (GHIT Fund) for research and development to combat infectious diseases including neglected tropical diseases.
[28 May 2016 – Geneva, Switzerland]
Move helps bring the disease to the attention of governments and funders
During the 69th World Health Assembly, the decision-making body of the World Health Organization (WHO), the devastating infection mycetoma has been added to WHO’s official list of ‘neglected tropical diseases,’ an important step in addressing the suffering of patients afflicted by this disease around the globe. Mycetoma becomes the 18th disease to be included on this list.
[24 May 2016 – Geneva, Switzerland]
A new joint initiative by the WHO and DNDi that seeks to develop new antibiotic treatments to address the major public health threat of antimicrobial resistance announced today that it has received the necessary seed funding to build its scientific strategy, initial R&D portfolio, and start-up team.
[The International Liver Congress 2016, Barcelona, Spain, 13 April 2016]
Potentially pan-genotypic combination of ravidasvir and sofosbuvir to be tested in Malaysia and Thailand with target price of under $300
The Drugs for Neglected Diseases initiative (DNDi) and the Egyptian drug manufacturer Pharco Pharmaceuticals have signed agreements covering the clinical testing and scale-up of a hepatitis C treatment regimen at a price of just under $300.
[Español] [Français] [Português]
[Putrajaya, 13 January 2016]
Joint Media Release: Ministry of Health Malaysia and the Drugs for Neglected Diseases initiative (DNDi)
The Drugs for Neglected Diseases initiative (DNDi) and the Ministry of Health of the Government of Malaysia have agreed to work together to develop a public health approach to Hepatitis C within the framework of the future National Strategic Plan on viral hepatitis. The immediate goal is to conduct clinical studies of promising new treatment regimens for Hepatitis C, to be followed by scale-up of treatment for patients, with the overall objective of ensuring equitable access to affordable and effective treatments for patients suffering from this disease in Malaysia.